Abstract:BACKGROUND: Microglia are very sensitive to environmental changes, often becoming activated by pathological conditions. Activated microglia can exert it dual role in injury and repair in various diseases of the central nervous system, including cerebral ischemia, Parkinson's disease, and mesenchymalAlzheimer's disease.OBJECTIVE: An immortal microglial cell line, BV2, was treated with varying concentrations of lipopolysaccharide (LPS) to induce a pathological situation. Supernatant was harvested and incubated with bone marrow mesenchymal stein cells and, concomitantly, bone marrow mesenchymal stein cell differentiation was observed.DESIGN: A controlled observation, in vitro experiment.SETTING: Department of Neurology, First Affiliated Hospital of China Medical University.MATERIALS: Five male 2-3-week-old Sprague Dawley rats were purchased from Animal Laboratory Center of China Medical University and included in this Study. The protocol was performed in accordance with ethical guidelines for the use and care of animals. The microglial cell line BV2 was produced by Cell Research Institute of Chinese Academy of Sciences. LPS was produced by Sigma Company, USA.METHODS: This study was performed in the Central Laboratory of China Medical University from September 2006 to March 2007. Rat femoral and tibial bone marrow wits collected for separation and primary culture of bone marrow mesenchymal stein cells. Bone marrow inesenchyrnal stein cell cultures were divided into 5 groups: control group, non-activated group, as well as low-, medium-, and high-dose LPS groups. In the control group, bone marrow mesenchymal stein cells were cultured with Dulbecco's modified Eagle's medium (DMEM) supplemented with fetal bovine serum (Volume fraction 0.1). In the non-activated group, bone marrow mesenchymal stem cells were incubated with non-activated BV2 supernatant. In the low-, medium-, and high-dose LPS groups, bone marrow inesenchyrnal stein cells were incubated with LPS (0.01, 0.1 and 1 mu g/L, respectively)-activated BV2 supernatant.MAIN OUTCOME MEASURES: Expression of glial fibrillary acidic protein (GFAP) and neuron-specific enolase (NSE) in bone marrow mesenchymal stein cells was detected by immunofluorescence staining.RESULTS: GFAP-positive cells were detected in each group; however, the greatest number were found in the high-dose LPS group. The number of GFAP-positive cells was significantly greater in the high- and medium-dose groups, compared to the control, non-activated, and low-close LPS groups (P < 0.05). However, there wits no significant difference between the medium- and high-dose LPS groups (P > 0.05). NSE-positive cells were also detected in each group. However, there was no significant difference between any two groups (P > 0.05).CONCLUSION: Microglia, when activated to some ertent, could induce neuroglial cell differentiation from bone marrow mesenchymal stein cells: however, they did not exhibit the capacity to markedly promote neuronal cell differentiation. When microglia are activated, the capacity to induce bone marrow mesenchymal stem cell differentiation reaches a peak level, but is not increased with greater activation rates.

Lps-Induced Prongf Synthesis and Release in the N9 and Bv2 Microglial Cells: A New Pathway Underling Microglial Toxicity in Neuroinflammation

Prolyl Endopeptidase is Revealed Following SILAC Analysis to Be a Novel Mediator of Human Microglial and THP‐1 Cell Neurotoxicity

Microglial Activation Induced by Neurodegeneration

Toxicity of lipopolysaccharide-induced activated microglia to oligodendrocyte precursor cells

IL-1β and TNF-α induce neurotoxicity through glutamate production: a potential role for neuronal glutaminase.

Inhibition of phagocytosis and lysosomal acidification suppresses neurotoxic prion peptide-induced NALP3 inflammasome activation in BV2 microglia.

Glutaminase in Microglia: A Novel Regulator of Neuroinflammation

Predominant release of lysosomal enzymes by newborn rat microglia after LPS treatment revealed by proteomic studies.

The NALP3 inflammasome is involved in neurotoxic prion peptide-induced microglial activation

The role of ZC3H12D-regulated TLR4-NF-κB pathway in LPS-induced pro-inflammatory microglial activation

Activation of BV2 microglia by lipopolysaccharide triggers an inflammatory reaction in PC12 cell apoptosis through a toll-like receptor 4-dependent pathway

Lipopolysaccharide-Activated Microglial-Induced Neuroglial Cell Differentiation in Bone Marrow Mesenchymal Stem Cells

Potential neuroprotective effects of anti‐cytokine antibodies against lipopolysaccharide‐induced microglial inflammation

Prion Peptide PrP106-126 Induces Inducible Nitric Oxide Synthase and Proinflammatory Cytokine Gene Expression Through the Activation of NF-κB in Macrophage Cells.

The Release of Lysosomal Pro-cathepsin L of BV-2 Cells Upon Lipopolysaccharide Stimulation and Its Toxicity to Neurons

Botulinum toxin type A-targeted SPP1 contributes to neuropathic pain by the activation of microglia pyroptosis

Inhibition of NK1R Attenuates LPS-induced Microglial Inflammation and Consequent Death of PC12 Cells.

C16 Peptide and Angiopoietin-1 Protect Against LPS-induced BV-2 Microglial Cell Inflammation.

The mechanisms of Porphyromonas gingivalis-derived outer membrane vesicles-induced neurotoxicity and microglia activation

Natural Compounds Oridonin and Shikonin Exhibit Potentially Beneficial Regulatory Effects on Select Functions of Microglia

NMDA receptor inhibitor MK801 alleviated pro-inflammatory polarization of BV-2 microglia cells